New combo therapy shows promise for rare eye cancer
Disease control
Completed
This study tested whether a combination of two drugs, nivolumab and relatlimab, can shrink tumors in people with metastatic uveal melanoma, a rare eye cancer that has spread. Twenty-seven participants received the treatment to see how many responded. The goal was to control the d…
Phase: PHASE2 • Sponsor: Jose Lutzky, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC